Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Belgium's TiGenix has obtained the manufacturing authorization for its European production facility in Sittard-Geleen, Netherlands.
Subscribe to our email newsletter
The move follows the cGMP inspection by the Dutch authorities.
TiGenix CEO Eduardo Bravo said the state-of-the-art manufacturing site is responsible for the production of innovative cell therapy products.
"It provides us with crucial manufacturing capabilities to support the anticipated growth in demand for ChondroCelect for cartilage repair, and has sufficient capacity for the production of our advanced stem cell therapy products," Bravo added.
TiGenix is a cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programs.